Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models

Summary

The antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold (LK-732, LK-639 and LK-731) and their amidoxime prodrugs (LK-658, LK-633 and LK-730) was studied in comparison to argatroban and nadroparin in two rat models of venous thrombosis, induced either by complete stasis combined with hypercoagulability (model 1) or by partial stasis combined with vessel injury (model 2). In initial experiments LK-732 was established as the most promising antithrombotic of the LK inhibitors and as such was further tested. In model 1, intravenous bolus administration of LK-732 produced a dose-dependent inhibition of thrombus formation with an ID50 value of 1.3 mg/kg. This ID50 value was approximately four times higher than the ID50 value of argatroban (0.3 mg/kg; p=0.011). However, in model 2, LK-732 and argatroban decreased thrombus weight by 50% at similar ID50 values (3.8 mg/kg vs 3.0 mg/kg, respectively; p=0.726). The ex vivo anticoagulant effect of LK-732 was substantially weaker compared to argatroban at doses that produced comparable antithrombotic effects. After subcutaneous administration, in vivo thrombus weight reduction of LK inhibitors (10 mg/kg) ranged between 22 to 48%. However, their oral antithrombotic effect at a dose of 30 mg/kg was rather low. LK amidoxime prodrugs failed to produce a substantial antithrombotic effect after subcutaneous (10 mg/ kg) as well as after oral administration (30 mg/kg). In conclusion, thrombin inhibitors built on the azaphenylalanine scaffold represent a new group of intravenously effective antithrombotics. However, optimisation of the oral antithrombotic effect of amid-oxime prodrug LK-658 of the lead inhibitor LK-732 is required for justifying further development of these inhibitors.

Keywords

Thrombin inhibitors - venous thrombosis model - rat - azaphenylalanine scaffold - prodrug

• References

• 1 Jenny SW, Mann KG. Thrombin. In: Hemostasis and thrombosis. Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN. Philadelphia-Tokio, Lippincott Williams & Wilkins; 2001: 171-89.
• 2 Tapparelli C, Metternich R, Ehrhardt C. et al. Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile. Trends Pharmacol Sci 1993; 14: 366-76.
• 3 Kaplan KL, Francis CW. Direct thrombin inhibitors. Semin Hematol 2002; 39: 187-96.
• 4 Gustafsson D. Oral direct thrombin inhibitors in clinical development. J Int Med 2003; 254: 322-34.
• 5 Weitz I J, Crowther M. Direct thrombin inhibitors. Thromb Res 2002; 106: 275-84.
• 6 Heit JA. The potential role of direct thrombin inhibitors in the prevention and treatment of venous thromboembolism. Chest 2003; 124: 40-8.
• 7 Fareed J. et al. Antithrombin agents as anticoagulants and antithrombotics: implications in drug development. Semin Hematol 1999; 36: 42-56.
• 8 Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. Br Med J 2002; 325: 828-31.
• 9 Kelton JG. Heparin induced thrombocytopenia: an overview. Blood Rev 2002; 16: 77-80.
• 10 Zega A, Mlinšek G, Šepic P. et al. Design and structure- activity relationship of thrombin inhibitors with an azaphenylalanine scaffold: potency and selectivity enhancements via P2 optimization. Bioorg Med Chem 2001; 9: 2745-56.
• 11 Zega A, Mlinšek G, Šolmajer T. et al. Thrombin inhibitors built on an azaphenylalanine scaffold. Bioorg Med Chem 2004; 14: 1563-7.
• 12 Vogel MTG. et al. Comparison of two experimental thrombosis models in rats: Effects of four glycosaminoglycans. Thromb Res 1989; 54: 399-410.
• 13 Gustafsson D, Nystrom JE, Carlsson S. et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: Intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101: 171-81.
• 14 Sato K, Kawasaki T, Hisamichi N. et al. Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time. Br J Pharmacol 1998; 123: 92-6.
• 15 Millet J. et al. The antithrombotic potential of dalteparin in man assessed indirectly by Wessler's technique. Thromb Haemost 1996; 76: 989-92.
• 16 Berry CN, Girard D, Lochot S. et al. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time. Br J Pharmacol 1994; 113: 1209-14.
• 17 Peternel L, Drevenšek G, Cerne M. et al. Evaluation of two experimental venous thrombosis models in the rat. Thromb Res. 2005. in press
• 18 Di Cera E. Thrombin interactions. Chest 2003; 124: 11S-7S.
• 19 Mann KG. Thrombin formation. Chest 2003; 124: 4S-10S.
• 20 Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci USA 1999; 96: 11023-7.
• 21 Brass LF. Thrombin and platelet activation. Chest 2003; 124: 18S-25S.
• 22 Nesheim M. Thrombin and fibrinolysis. Chest 2003; 124: S33-9S.
• 23 Minami T, Sugiyama A, Wu SQ. et al. Thrombin and phenotypic modulation of the endothelium. Arterioscler Thromb Vasc Biol 2004; 24: 41-53.
• 24 Nilsson T, Sjoling-Ericksson A, Deinum J. The mechanism of binding of low-molecular-weight active site inhibitors to human alpha-thrombin. J Enzyme Inhib 1998; 13: 11-29.
• 25 Clement B. Reduction of N-hydroxylated compounds: amidoximes (N-hydroxyamidines) as prodrugs of amidines. Drug Metab Rev 2002; 34: 565-79.
• 26 Hall JE. et al. Anti-pneumocystis activities of aromatic diamidoxime prodrugs. Antimicrob Agents Chemother 1998; 42: 666-74.
• 27 Hauptmann J. Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs. A review of small-molecule thrombin inhibitors. Eur J Clin Pharm 2002; 57: 751-8.
• 28 Hauptmann J. et al. Reduction of a benzamidoxime derivative to the corresponding benzamidine in vivo and in vitro. Pharmazie 1988; 43: 559-60.
• 29 Clement B. et al. Genotoxic activities of benzamidine and its N-hydroxylated metabolite benzamidoxime in Salmonella typhimurium and mammalian cells. J Cancer Res Clin Oncol 1988; 114: 363-8.